| Overall survival (n = 719) |  | Progression-free survival (n = 641) | ||||
---|---|---|---|---|---|---|---|
N | HR (95% CI) | p value | Â | N | HR (95% CI) | p value | |
Gender | Â | Â | Â | Â | Â | Â | Â |
 Female | 317 | 0.29 (0.19–0.45) | 2.3e−09 |  | 235 | 1.99 (1.25–3.17) | 0.0032 |
 Male | 344 | 0.49 (0.34–0.68) | 2.6e−05 |  | 226 | 2.96 (1.86–4.7) | 1.5e−06 |
Stage | Â | Â | Â | Â | Â | Â | Â |
 1 | 370 | 0.34 (0.22–0.52) | 2.1e−07 |  | 283 | 2.75 (1.65–4.61) | 5.8e−05 |
 2 | 136 | 0.43 (0.26–0.72) | 8e−04 |  | 103 | 1.38 (0.8–2.4) | 0.25 |
 3 | 24 | 0.72 (0.25–2.07) | 0.54 |  | 10 | – | – |
 4 | 4 | – | – |  | 0 | – | – |
T stage | Â | Â | Â | Â | Â | Â | Â |
 1 | 123 | 0.67 (0.36–1.24) | 0.2 |  | 47 | 7.47 (0.89–62.42) | 0.029 |
 2 | 105 | 0.77 (0.44–1.33) | 0.34 |  | 93 | 1.59 (0.84–3.01) | 0.15 |
 3 | 4 | – | – |  | 2 | – | – |
 4 | 0 | – | – |  | 0 | – | – |
N stage | Â | Â | Â | Â | Â | Â | Â |
 0 | 184 | 1.87 (1.14–3.05) | 0.011 |  | 102 | 1.49 (0.68–3.25) | 0.31 |
 1 | 44 | 1.18 (0.54–2.57) | 0.68 |  | 38 | 3.16 (1.23–8.13) | 0.012 |
 2 | 3 | – | – |  | 2 | – | – |
M stage | Â | Â | Â | Â | Â | Â | Â |
 0 | 231 | 1.56 (1.04–2.34) | 0.028 |  | 142 | 2.17 (1.19–3.93) | 0.0093 |
 1 | 1 | – | – |  | 0 | – | – |
Smoke | Â | Â | Â | Â | Â | Â | Â |
 Ever | 246 | 2.03 (1.25–3.28) | 0.0033 |  | 243 | 2.29(1.46–3.6) | 0.00021 |
 Never | 143 | 3.42 (1.35–8.62) | 0.0057 |  | 143 | 3.1 (1.58–6.07) | 5e−04 |